AstraZeneca (NASDAQ:AZN) Trading Up 2.9%

Shares of AstraZeneca PLC (NASDAQ:AZN) were up 2.9% during mid-day trading on Friday . The stock traded as high as $61.27 and last traded at $61.18. Approximately 152,558 shares traded hands during trading, a decline of 98% from the average daily volume of 9,892,515 shares. The stock had previously closed at $59.48.

AZN has been the subject of several recent research reports. UBS Group restated a “buy” rating on shares of AstraZeneca in a report on Thursday, June 17th. Morgan Stanley restated an “overweight” rating on shares of AstraZeneca in a report on Friday, September 17th. SVB Leerink increased their target price on shares of AstraZeneca from $69.00 to $71.00 and gave the stock an “outperform” rating in a report on Monday, September 20th. Citigroup restated a “buy” rating on shares of AstraZeneca in a report on Wednesday, July 21st. Finally, JPMorgan Chase & Co. began coverage on shares of AstraZeneca in a report on Thursday, August 12th. They set an “overweight” rating for the company. One analyst has rated the stock with a sell rating, two have issued a hold rating and eleven have assigned a buy rating to the company. According to data from MarketBeat.com, the company has an average rating of “Buy” and an average price target of $123.00.

The company has a debt-to-equity ratio of 1.54, a current ratio of 1.23 and a quick ratio of 1.01. The company’s 50-day moving average price is $57.87 and its two-hundred day moving average price is $55.70. The company has a market capitalization of $186.98 billion, a P/E ratio of 41.91, a price-to-earnings-growth ratio of 1.21 and a beta of 0.53.

AstraZeneca (NASDAQ:AZN) last issued its quarterly earnings results on Wednesday, July 28th. The company reported $0.45 EPS for the quarter, beating analysts’ consensus estimates of $0.43 by $0.02. AstraZeneca had a net margin of 12.77% and a return on equity of 40.02%. The business had revenue of $8.22 billion for the quarter, compared to analysts’ expectations of $7.79 billion. On average, analysts anticipate that AstraZeneca PLC will post 2.64 earnings per share for the current fiscal year.

The firm also recently declared a semi-annual dividend, which was paid on Monday, September 13th. Shareholders of record on Friday, August 13th were given a dividend of $0.45 per share. This represents a yield of 2.4%. The ex-dividend date of this dividend was Thursday, August 12th. AstraZeneca’s payout ratio is currently 68.16%.

Several large investors have recently added to or reduced their stakes in the company. Price T Rowe Associates Inc. MD boosted its stake in shares of AstraZeneca by 212.1% during the first quarter. Price T Rowe Associates Inc. MD now owns 58,047,130 shares of the company’s stock valued at $2,886,103,000 after purchasing an additional 39,450,439 shares during the period. Capital International Investors boosted its stake in shares of AstraZeneca by 6.4% during the second quarter. Capital International Investors now owns 32,049,323 shares of the company’s stock valued at $1,921,014,000 after purchasing an additional 1,935,945 shares during the period. Fisher Asset Management LLC boosted its stake in shares of AstraZeneca by 2.4% during the second quarter. Fisher Asset Management LLC now owns 18,830,493 shares of the company’s stock valued at $1,127,947,000 after purchasing an additional 441,805 shares during the period. GQG Partners LLC boosted its stake in shares of AstraZeneca by 7.9% during the second quarter. GQG Partners LLC now owns 16,632,033 shares of the company’s stock valued at $995,898,000 after purchasing an additional 1,220,580 shares during the period. Finally, BlackRock Inc. lifted its stake in AstraZeneca by 14.5% in the first quarter. BlackRock Inc. now owns 13,809,955 shares of the company’s stock worth $686,632,000 after acquiring an additional 1,747,324 shares during the period. 13.88% of the stock is owned by hedge funds and other institutional investors.

AstraZeneca Company Profile (NASDAQ:AZN)

AstraZeneca Plc is a holding company, which engages in the research, development, and manufacture of pharmaceutical products. Its pipeline are used for the following therapy areas: oncology, cardiovascular, renal, metabolism, and respiratory. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.

See Also: What is the QQQ ETF?

Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.